![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IL18 |
Gene summary for IL18 |
![]() |
Gene information | Species | Human | Gene symbol | IL18 | Gene ID | 3606 |
Gene name | interleukin 18 | |
Gene Alias | IGIF | |
Cytomap | 11q23.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024R3E0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3606 | IL18 | CA_HPV_1 | Human | Cervix | CC | 7.17e-07 | -4.13e-01 | 0.0264 |
3606 | IL18 | CA_HPV_3 | Human | Cervix | CC | 1.54e-06 | 2.78e-01 | 0.0414 |
3606 | IL18 | CCII_1 | Human | Cervix | CC | 3.98e-14 | -7.13e-01 | 0.3249 |
3606 | IL18 | Tumor | Human | Cervix | CC | 5.19e-14 | -5.76e-01 | 0.1241 |
3606 | IL18 | sample1 | Human | Cervix | CC | 2.68e-02 | -5.01e-01 | 0.0959 |
3606 | IL18 | sample3 | Human | Cervix | CC | 2.27e-20 | -6.28e-01 | 0.1387 |
3606 | IL18 | H2 | Human | Cervix | HSIL_HPV | 3.77e-09 | -4.52e-01 | 0.0632 |
3606 | IL18 | L1 | Human | Cervix | CC | 2.51e-06 | -5.40e-01 | 0.0802 |
3606 | IL18 | T1 | Human | Cervix | CC | 6.31e-12 | -5.72e-01 | 0.0918 |
3606 | IL18 | T3 | Human | Cervix | CC | 7.25e-20 | -6.31e-01 | 0.1389 |
3606 | IL18 | LZE4T | Human | Esophagus | ESCC | 3.34e-05 | -4.28e-03 | 0.0811 |
3606 | IL18 | LZE8T | Human | Esophagus | ESCC | 3.36e-02 | -1.10e-01 | 0.067 |
3606 | IL18 | P1T-E | Human | Esophagus | ESCC | 6.47e-05 | -2.62e-02 | 0.0875 |
3606 | IL18 | P2T-E | Human | Esophagus | ESCC | 9.22e-04 | -2.95e-01 | 0.1177 |
3606 | IL18 | P4T-E | Human | Esophagus | ESCC | 6.80e-12 | 5.69e-01 | 0.1323 |
3606 | IL18 | P5T-E | Human | Esophagus | ESCC | 7.84e-28 | 1.01e+00 | 0.1327 |
3606 | IL18 | P9T-E | Human | Esophagus | ESCC | 2.13e-11 | 4.21e-01 | 0.1131 |
3606 | IL18 | P10T-E | Human | Esophagus | ESCC | 2.68e-07 | 3.22e-01 | 0.116 |
3606 | IL18 | P12T-E | Human | Esophagus | ESCC | 3.83e-03 | -2.18e-01 | 0.1122 |
3606 | IL18 | P16T-E | Human | Esophagus | ESCC | 3.71e-08 | -3.19e-01 | 0.1153 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00456194 | Oral cavity | OSCC | regulation of lymphocyte differentiation | 83/7305 | 174/18723 | 1.18e-02 | 4.00e-02 | 83 |
GO:00027022 | Oral cavity | OSCC | positive regulation of production of molecular mediator of immune response | 58/7305 | 117/18723 | 1.28e-02 | 4.27e-02 | 58 |
GO:00313495 | Oral cavity | OSCC | positive regulation of defense response | 127/7305 | 278/18723 | 1.32e-02 | 4.39e-02 | 127 |
GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
GO:00706657 | Oral cavity | OSCC | positive regulation of leukocyte proliferation | 72/7305 | 150/18723 | 1.53e-02 | 4.95e-02 | 72 |
GO:005109213 | Oral cavity | LP | positive regulation of NF-kappaB transcription factor activity | 61/4623 | 152/18723 | 1.82e-05 | 3.11e-04 | 61 |
GO:005109015 | Oral cavity | LP | regulation of DNA-binding transcription factor activity | 147/4623 | 440/18723 | 2.00e-05 | 3.35e-04 | 147 |
GO:190122212 | Oral cavity | LP | regulation of NIK/NF-kappaB signaling | 44/4623 | 112/18723 | 4.38e-04 | 4.19e-03 | 44 |
GO:004544512 | Oral cavity | LP | myoblast differentiation | 35/4623 | 84/18723 | 4.56e-04 | 4.33e-03 | 35 |
GO:003249618 | Oral cavity | LP | response to lipopolysaccharide | 112/4623 | 343/18723 | 4.90e-04 | 4.60e-03 | 112 |
GO:007121616 | Oral cavity | LP | cellular response to biotic stimulus | 84/4623 | 246/18723 | 5.17e-04 | 4.82e-03 | 84 |
GO:190122413 | Oral cavity | LP | positive regulation of NIK/NF-kappaB signaling | 29/4623 | 69/18723 | 1.15e-03 | 9.40e-03 | 29 |
GO:003806112 | Oral cavity | LP | NIK/NF-kappaB signaling | 52/4623 | 143/18723 | 1.20e-03 | 9.66e-03 | 52 |
GO:005109114 | Oral cavity | LP | positive regulation of DNA-binding transcription factor activity | 86/4623 | 260/18723 | 1.35e-03 | 1.08e-02 | 86 |
GO:000223718 | Oral cavity | LP | response to molecule of bacterial origin | 115/4623 | 363/18723 | 1.42e-03 | 1.13e-02 | 115 |
GO:0045785110 | Oral cavity | LP | positive regulation of cell adhesion | 134/4623 | 437/18723 | 2.44e-03 | 1.74e-02 | 134 |
GO:0045661 | Oral cavity | LP | regulation of myoblast differentiation | 22/4623 | 51/18723 | 2.96e-03 | 2.03e-02 | 22 |
GO:007122214 | Oral cavity | LP | cellular response to lipopolysaccharide | 69/4623 | 209/18723 | 3.99e-03 | 2.59e-02 | 69 |
GO:004211017 | Oral cavity | LP | T cell activation | 146/4623 | 487/18723 | 4.13e-03 | 2.66e-02 | 146 |
GO:190370619 | Oral cavity | LP | regulation of hemopoiesis | 111/4623 | 367/18723 | 8.48e-03 | 4.60e-02 | 111 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa0513416 | Cervix | CC | Legionellosis | 20/1267 | 57/8465 | 1.29e-04 | 8.19e-04 | 4.85e-04 | 20 |
hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0532314 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0513517 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa0513417 | Cervix | CC | Legionellosis | 20/1267 | 57/8465 | 1.29e-04 | 8.19e-04 | 4.85e-04 | 20 |
hsa0516415 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0532315 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
hsa051521 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
IL18 | IL18R1_IL18RAP | IL18_IL18R1_IL18RAP | IL1 | Liver | Healthy |
IL18 | IL18R1_IL18RAP | IL18_IL18R1_IL18RAP | IL1 | Lung | AAH |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL18 | SNV | Missense_Mutation | c.212N>T | p.Asp71Val | p.D71V | Q14116 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD | |
IL18 | SNV | Missense_Mutation | novel | c.48N>A | p.Met16Ile | p.M16I | Q14116 | protein_coding | tolerated(0.1) | benign(0.006) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
IL18 | insertion | Nonsense_Mutation | novel | c.401_402insATAATGTTTAAAAAATTCATAGTTTGAAAACATTCT | p.Asp134delinsGluTerCysLeuLysAsnSerTerPheGluAsnIleLeu | p.D134delinsE*CLKNS*FENIL | Q14116 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
IL18 | SNV | Missense_Mutation | c.146G>C | p.Arg49Thr | p.R49T | Q14116 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3697-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IL18 | SNV | Missense_Mutation | novel | c.328C>A | p.Leu110Ile | p.L110I | Q14116 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IL18 | SNV | Missense_Mutation | novel | c.53T>G | p.Phe18Cys | p.F18C | Q14116 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IL18 | deletion | Frame_Shift_Del | c.528delA | p.Glu177ArgfsTer9 | p.E177Rfs*9 | Q14116 | protein_coding | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
IL18 | SNV | Missense_Mutation | novel | c.539N>C | p.Leu180Ser | p.L180S | Q14116 | protein_coding | tolerated(0.48) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IL18 | SNV | Missense_Mutation | novel | c.527N>C | p.Lys176Thr | p.K176T | Q14116 | protein_coding | deleterious(0.02) | benign(0.303) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IL18 | SNV | Missense_Mutation | c.551C>A | p.Ser184Tyr | p.S184Y | Q14116 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3606 | IL18 | DRUGGABLE GENOME | PPD | 11882036 | ||
3606 | IL18 | DRUGGABLE GENOME | MEDI-2338 | MEDI-2338 | 24812504 | |
3606 | IL18 | DRUGGABLE GENOME | tacrolimus | TACROLIMUS | 25712187,25487141 | |
3606 | IL18 | DRUGGABLE GENOME | MYCOPHENOLIC ACID | 12907250 | ||
3606 | IL18 | DRUGGABLE GENOME | POLYPHENOL | 16143535 | ||
3606 | IL18 | DRUGGABLE GENOME | Iboctadekin | IBOCTADEKIN | ||
3606 | IL18 | DRUGGABLE GENOME | COLCHICINE | COLCHICINE | 15281431 | |
3606 | IL18 | DRUGGABLE GENOME | THYROXINE | THYROXINE | 16061828 | |
3606 | IL18 | DRUGGABLE GENOME | Iboctadekin + Doxil | |||
3606 | IL18 | DRUGGABLE GENOME | Iboctadekin + rituximab |
Page: 1 2 |